Barclays Raises CME Group Price Target to $344

Equities researchers boost price objective on financial services provider's stock

Apr. 8, 2026 at 1:54pm

Barclays has increased its price target on shares of CME Group (NASDAQ:CME) from $312.00 to $344.00 and maintained an 'equal weight' rating on the stock. The new price target represents a potential upside of 13.90% from the company's current trading price.

Why it matters

This price target increase by a major investment bank signals that analysts see further upside potential in CME Group's stock, which could be of interest to investors tracking the financial services provider's performance and growth prospects.

The details

In a research report issued to clients and investors, Barclays cited the company's strong financial position and market leadership as factors behind the higher price target. CME Group operates some of the world's largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange, the Chicago Board of Trade, and the New York Mercantile Exchange.

  • Barclays issued the updated price target and rating on April 8, 2026.

The players

Barclays

A major global investment bank that provides financial services and research coverage on public companies.

CME Group

A leading global markets company that operates major derivatives exchanges and provides trading, clearing, and data services.

Got photos? Submit your photos here. ›

The takeaway

This price target increase by Barclays suggests that the investment bank sees continued growth potential for CME Group, a leading player in the global derivatives and financial services market.